Reducing the costs of phase III cardiovascular clinical trials

Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction

Marc A. Pfeffer, Eugene Braunwald, Lemuel A. Moyé et al. · New England Journal of Medicine · 1992 · 6K citations

Medicine, Cardiology, Pharmacology +13

The price of innovation: new estimates of drug development costs

Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski · Journal of Health Economics · 2003 · 4.3K citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +14

A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction

Lars Køber, Christian Torp‐Pedersen, Jan E. Carlsen et al. · New England Journal of Medicine · 1995 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacology +14

Why do we need some large, simple randomized trials?

Salim Yusuf, Rory Collins, Richard Peto · Statistics in Medicine · 1984 · 714 citations

Public Health, Biostatistics, Experimental Design +8

Gains in Life Expectancy from Medical Interventions — Standardizing Data on Outcomes

Janice C. Wright, Milton C. Weinstein · New England Journal of Medicine · 1998 · 340 citations

Social Sciences, Health Policy, Preventive Medicine +11